PMID- 36977112
OWN - NLM
STAT- MEDLINE
DCOM- 20230330
LR  - 20230410
IS  - 2072-6651 (Electronic)
IS  - 2072-6651 (Linking)
VI  - 15
IP  - 3
DP  - 2023 Mar 15
TI  - Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet 
      Obstruction and Post-Deobstructive Prostate Surgery.
LID - 10.3390/toxins15030221 [doi]
LID - 221
AB  - PURPOSE: A significant proportion of men without bladder outlet obstruction (BOO) 
      have been reported to have overactive bladders (OAB). This article aimed to 
      review the specific group of reports on the use of botulinum toxin type A (BTX-A) 
      injections into the bladder wall. MATERIALS AND METHODS: Original articles 
      reporting men with small prostates without BOO were identified through a 
      literature search using the PubMed and EMBASE databases. Finally, we included 18 
      articles that reviewed the efficacy and adverse effects of BTX-A injections in 
      men. RESULTS: Of the 18 articles screened, 13 demonstrated the therapeutic 
      efficacy and adverse effects of BTX-A injections in men. Three studies compared 
      BTX-A injection response between patients without prior prostate surgery and 
      those undergoing prior prostate surgery, including transurethral resection of the 
      prostate and radical prostatectomy (RP). Patients with prior RP experienced 
      better efficacy and had a low risk of side effects. Two studies focused on 
      patients who had undergone prior surgery for stress urinary incontinence, 
      including male sling and artificial urethral sphincter surgery. The BTX-A 
      injection was a safe and effective procedure for this specific group. OAB in men 
      was found to have a different pathophysiology mechanism from that in female 
      patients, which may decrease the efficacy of BTX-A injection in men. However, 
      patients with small prostates and low prostate-specific antigen levels 
      demonstrated better efficacy and tolerability after BTX-A injection. CONCLUSIONS: 
      Although intravesical injection of BTX-A was a good option for controlling 
      refractory OAB in men, the evidence-based guidelines are still limited. Further 
      research is necessary to better understand the role of BTX-A injections on 
      various aspects and histories. Therefore, treating patients using strategies 
      tailored to their individual conditions is important.
FAU - Lee, Hsiang-Ying
AU  - Lee HY
AUID- ORCID: 0000-0003-2405-4874
AD  - Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung 80756, 
      Taiwan.
AD  - Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 80756, Taiwan.
AD  - Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung 80756, Taiwan.
AD  - Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 80756, 
      Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AUID- ORCID: 0000-0001-7165-4771
AD  - Department of Urology, School of Medicine, Tzu Chi University, Hualien 970473, 
      Taiwan.
AD  - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, Hualien 970473, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230315
PL  - Switzerland
TA  - Toxins (Basel)
JT  - Toxins
JID - 101530765
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - 0 (Neuromuscular Agents)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - *Botulinum Toxins, Type A/adverse effects
MH  - Prostate/surgery
MH  - Administration, Intravesical
MH  - *Neuromuscular Agents/adverse effects
MH  - *Transurethral Resection of Prostate
MH  - *Urinary Bladder Neck Obstruction/drug therapy/surgery
MH  - *Urinary Bladder, Overactive/drug therapy
MH  - Treatment Outcome
PMC - PMC10057732
OTO - NOTNLM
OT  - botulinum toxin
OT  - men
OT  - overactive bladder
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/29 06:00
MHDA- 2023/03/30 06:11
PMCR- 2023/03/15
CRDT- 2023/03/28 15:13
PHST- 2023/01/16 00:00 [received]
PHST- 2023/02/16 00:00 [revised]
PHST- 2023/03/09 00:00 [accepted]
PHST- 2023/03/30 06:11 [medline]
PHST- 2023/03/28 15:13 [entrez]
PHST- 2023/03/29 06:00 [pubmed]
PHST- 2023/03/15 00:00 [pmc-release]
AID - toxins15030221 [pii]
AID - toxins-15-00221 [pii]
AID - 10.3390/toxins15030221 [doi]
PST - epublish
SO  - Toxins (Basel). 2023 Mar 15;15(3):221. doi: 10.3390/toxins15030221.